Macro- and microvascular disease in systemic sclerosis

Vascular Pharmacology

Volumn 71, Issue , 2015, Pages 16-23

  Kavian, Niloufar ^a,b   Batteux, Frédéric ^a,b  

^a INSTITUT COCHIN   (France)

^b AP HP ^*  (France)

Author keywords

Angiogenesis; Endo mesenchymal transistion; Endothelial cells; Pericytes; Reactive oxygen species; Systemic sclerosis; Vasculogenesis; Vasculopathy

Indexed keywords

AUTOANTIBODY; TRANSCRIPTION FACTOR;

ANGIOGENESIS; ATHEROGENESIS; BLOOD CLOTTING; ENDOTHELIUM; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MICROANGIOPATHY; MICROVASCULATURE; NONHUMAN; PATHOPHYSIOLOGY; PERICYTE; PRIORITY JOURNAL; REVIEW; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; ANIMAL; METABOLISM; PATHOLOGY; PHYSIOLOGY; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD COAGULATION; ENDOTHELIUM, VASCULAR; HUMANS; MICROVESSELS; PLATELET ACTIVATION; SCLERODERMA, SYSTEMIC; VASCULAR DISEASES;

EID: 84937975421     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.05.015     Document Type: Review

References (92)

1. Toubi E., Kessel A., Bamberger E., et al. Systemic lupus erythematosus vasculitis: a current therapeutic overview. Curr. Treat. Options Cardiovasc. Med. Apr 2004, 6(2):87-97.
2. Prasad M., Hermann J., Gabriel S.E., et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat. Rev. Cardiol. 2014, 12(3):168-176.
3. Koch A.E., Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res. Ther. 2007, 9(Suppl. 2):S3.
4. LeRoy E.C., Black C., Fleischmajer R., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. Feb 1988, 15(2):202-205.
5. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N. Engl. J. Med. May 7 2009, 360(19):1989-2003.
6. Akimoto S., Ishikawa O., Tamura T., et al. Antineutrophil cytoplasmic autoantibodies in patients with systemic sclerosis. Br. J. Dermatol. Mar 1996, 134(3):407-410.
7. Locke I.C., Worrall J.G., Leaker B., et al. Autoantibodies to myeloperoxidase in systemic sclerosis. J. Rheumatol. Jan 1997, 24(1):86-89.
8. Ruffatti A., Sinico R.A., Radice A., et al. Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis. J. Rheumatol. May 2002, 29(5):918-923.
9. Arad U., Balbir-Gurman A., Doenyas-Barak K., et al. Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin. Arthritis Rheum. Oct 2011, 41(2):223-229.
10. Derrett-Smith E.C., Nihtyanova S.I., Harvey J., et al. Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors. Rheumatology (Oxford) Oct 2013, 52(10):1824-1831.
11. Block J.A., Sequeira W. Raynaud's phenomenon. Lancet Jun 23 2001, 357(9273):2042-2048.
12. Kahaleh B. Progress in research into systemic sclerosis. Lancet Aug 14-20, 2004, 364(9434):561-562.
13. Walker J.G., Stirling J., Beroukas D., et al. Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosis. Pathology Jun 2005, 37(3):220-225.
14. Mukerjee D., St George D., Coleiro B., et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann. Rheum. Dis. Nov 2003, 62(11):1088-1093.
15. Proudman S.M., Stevens W.M., Sahhar J., et al. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Int. Med. J. Jul 2007, 37(7):485-494.
16. Farber H.W., Loscalzo J. Pulmonary arterial hypertension. N. Engl. J. Med. Oct 14 2004, 351(16):1655-1665.
17. Steen V.D., Medsger T.A., Osial T.A., et al. Factors predicting development of renal involvement in progressive systemic sclerosis. Am. J. Med. May 1984, 76(5):779-786.
18. Hung E.W., Mayes M.D., Sharif R., et al. Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. J. Rheumatol. Apr 2013, 40(4):455-460.
19. Ghrenassia E., Avouac J., Khanna D., et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J. Rheumatol. Jan 2014, 41(1):99-105.
20. Marie I., Ducrotte P., Antonietti M., et al. Watermelon stomach in systemic sclerosis: its incidence and management. Aliment. Pharmacol. Ther. Aug 15 2008, 28(4):412-421.
21. Marie I., Levesque H., Ducrotte P., et al. Gastric involvement in systemic sclerosis: a prospective study. Am. J. Gastroenterol. Jan 2001, 96(1):77-83.
22. Laoubi K., Allanore Y., Chaussade S., et al. Watermelon stomach in systemic sclerosis. J. Mal. Vasc. Jul 2010, 35(4):250-253.
23. Norton W.L., Nardo J.M. Vascular disease in progressive systemic sclerosis (scleroderma). Ann. Intern. Med. Aug 1970, 73(2):317-324.
24. Steen V. The heart in systemic sclerosis. Curr. Rheumatol. Rep. Apr 2004, 6(2):137-140.
25. Bulkley B.H., Ridolfi R.L., Salyer W.R., et al. Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation Mar 1976, 53(3):483-490.
26. Bulkley B.H., Klacsmann P.G., Hutchins G.M. Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clinicopathologic study of 9 patients with progressive systemic sclerosis. Am. Heart J. May 1978, 95(5):563-569.
27. D'Angelo W.A., Fries J.F., Masi A.T., et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am. J. Med. Mar 1969, 46(3):428-440.
28. Akram M.R., Handler C.E., Williams M., et al. Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford) Nov 2006, 45(11):1395-1398.
29. Averbuch-Heller L., Steiner I., Abramsky O. Neurologic manifestations of progressive systemic sclerosis. Arch. Neurol. Dec 1992, 49(12):1292-1295.
30. Youssef P., Brama T., Englert H., et al. Limited scleroderma is associated with increased prevalence of macrovascular disease. J. Rheumatol. Mar 1995, 22(3):469-472.
31. Veale D.J., Collidge T.A., Belch J.J. Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann. Rheum. Dis. Oct 1995, 54(10):853-855.
32. Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat. Rev. Rheumatol. Aug 2010, 6(8):453-460.
33. Cutolo M., Sulli A., Pizzorni C., et al. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J. Rheumatol. Jan 2000, 27(1):155-160.
34. Campbell P.M., LeRoy E.C. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin. Arthritis Rheum. May 1975, 4(4):351-368.
35. Rabquer B.J., Koch A.E. Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr. Rheumatol. Rep. Feb 2012, 14(1):56-63.
36. Kahaleh M.B., Osborn I., LeRoy E.C. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann. Intern. Med. Apr 1981, 94(4pt 1):482-484.
37. Freemont A.J., Hoyland J., Fielding P., et al. Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br. J. Dermatol. Jun 1992, 126(6):561-568.
38. Kahaleh M.B., LeRoy E.C. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 1999, 31(3):195-214.
39. Liakouli V., Cipriani P., Marrelli A., et al. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun. Rev. Aug 2011, 10(10):590-594.
40. Sulli A., Soldano S., Pizzorni C., et al. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J. Rheumatol. Jun 2009, 36(6):1235-1239.
41. Avouac J., Vallucci M., Smith V., et al. Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis. Arthritis Res. Ther. 2013, 15(2):R55.
42. Abraham D.J., Vancheeswaran R., Dashwood M.R., et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. Sep 1997, 151(3):831-841.
43. Sinici I., Kalyoncu U., Karahan S., et al. Endothelial nitric oxide gene polymorphism and risk of systemic sclerosis: predisposition effect of T-786C promoter and protective effect of 27bp repeats in Intron 4. Clin. Exp. Rheumatol. Mar-Apr 2010, 28(2):169-175.
44. Higley H., Persichitte K., Chu S., et al. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum. Feb 1994, 37(2):278-288.
45. Lafyatis R. Transforming growth factor beta-at the centre of systemic sclerosis. Nat. Rev. Rheumatol. Dec 2014, 10(12):706-719.
46. Servettaz A., Guilpain P., Goulvestre C., et al. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann. Rheum. Dis. Sep 2007, 66(9):1202-1209.
47. Tikly M., Marshall S.E., Haldar N.A., et al. Oxygen free radical scavenger enzyme polymorphisms in systemic sclerosis. Free Radic. Biol. Med. Jun 1 2004, 36(11):1403-1407.
48. Allanore Y., Borderie D., Lemarechal H., et al. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am. J. Med. May 1 2004, 116(9):595-600.
49. Rosato E., Borghese F., Pisarri S., et al. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin. Rheumatol. Dec 2009, 28(12):1379-1384.
50. Servettaz A., Goulvestre C., Kavian N., et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J. Immunol. May 1 2009, 182(9):5855-5864.
51. Grimminger F., Weimann G., Frey R., et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur. Respir. J. Apr 2009, 33(4):785-792.
52. Ghofrani H.A., Galie N., Grimminger F., et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. Jul 25 2013, 369(4):330-340.
53. De LaVega A.J., Derk C.T. Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication. Expert. Opin. Investig. Drugs Jan 2009, 18(1):23-29.
54. Roustit M., Blaise S., Allanore Y., et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann. Rheum. Dis. Oct 2013, 72(10):1696-1699.
55. Distler J.H., Jungel A., Huber L.C., et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc. Natl. Acad. Sci. U. S. A. Feb 22 2005, 102(8):2892-2897.
56. Rajkumar V.S., Howell K., Csiszar K., et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res. Ther. 2005, 7(5):R1113-R1123.
57. Rajkumar V.S., Sundberg C., Abraham D.J., et al. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum. May 1999, 42(5):930-941.
58. Kavian N., Servettaz A., Marut W., et al. Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor beta in the skin of mice with scleroderma-like features and prevents the development of the disease. Arthritis Rheum. Jun 2011, 64(6):1990-2000.
59. Lin S.L., Kisseleva T., Brenner D.A., et al. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. Dec 2008, 173(6):1617-1627.
60. Humphreys B.D., Lin S.L., Kobayashi A., et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. Jan 2010, 176(1):85-97.
61. Fleming J.N., Schwartz S.M. The pathology of scleroderma vascular disease. Rheum. Dis. Clin. N. Am. Feb 2008, 34(1):41-55. (vi).
62. Jimenez S.A. Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis. ISRN Rheumatol. 2013, 2013:835948.
63. Kavian N., Servettaz A., Mongaret C., et al. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum. Nov 2010, 62(11):3477-3487.
64. Kavian N., Servettaz A., Weill B., et al. New insights into the mechanism of notch signalling in fibrosis. Open Rheumatol. J. 2012, 6:96-102.
65. Choi J.J., Min D.J., Cho M.L., et al. Elevated vascular endothelial growth factor in systemic sclerosis. J. Rheumatol. Jul 2003, 30(7):1529-1533.
66. Manetti M., Guiducci S., Ibba-Manneschi L., et al. Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant. Trends Cardiovasc. Med. Oct 2011, 21(7):204-210.
67. Manetti M., Guiducci S., Romano E., et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ. Res. Jul 22 2011, 109(3):e14-e26.
68. Hummers L.K., Hall A., Wigley F.M., et al. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J. Rheumatol. Mar 2009, 36(3):576-582.
69. Distler O., Distler J.H., Scheid A., et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ. Res. Jul 9 2004, 95(1):109-116.
70. Schultz-Cherry S., Chen H., Mosher D.F., et al. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J. Biol. Chem. Mar 31 1995, 270(13):7304-7310.
71. Lawler P.R., Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb. Perspect. Med. May 2012, 2(5):a006627.
72. Rabquer B.J., Tsou P.S., Hou Y., et al. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res. Ther. 2011, 13(1):R18.
73. van Bon L., Affandi A.J., Broen J., et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N. Engl. J. Med. Jan 30 2014, 370(5):433-443.
74. Liu Z., Lebrin F., Maring J.A., et al. ENDOGLIN is dispensable for vasculogenesis, but required for vascular endothelial growth factor-induced angiogenesis. PLoS One 2014, 9(1):e86273.
75. Wipff J., Avouac J., Borderie D., et al. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology (Oxford) Jul 2008, 47(7):972-975.
76. Tanaka K., Sata M., Hirata Y., et al. Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ. Res. Oct 17 2003, 93(8):783-790.
77. Avouac J., Juin F., Wipff J., et al. Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann. Rheum. Dis. Oct 2008, 67(10):1455-1460.
78. Zhu S., Evans S., Yan B., et al. Transcriptional regulation of Bim by FOXO3a and Akt mediates scleroderma serum-induced apoptosis in endothelial progenitor cells. Circulation Nov 18 2008, 118(21):2156-2165.
79. Cerinic M.M., Valentini G., Sorano G.G., et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin. Arthritis Rheum. Apr 2003, 32(5):285-295.
80. Pattanaik D., Brown M., Postlethwaite A.E. Vascular involvement in systemic sclerosis (scleroderma). J. Inflamm. Res. 2011, 4:105-125.
81. Greaves M., Malia R.G., Milford Ward A., et al. Elevated von Willebrand factor antigen in systemic sclerosis: relationship to visceral disease. Br. J. Rheumatol. Aug 1988, 27(4):281-285.
82. Ames P.R., Lupoli S., Alves J., et al. The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. Br. J. Rheumatol. Oct 1997, 36(10):1045-1050.
83. Postlethwaite A.E., Chiang T.M. Platelet contributions to the pathogenesis of systemic sclerosis. Curr. Opin. Rheumatol. Nov 2007, 19(6):574-579.
84. Chiang T.M., Postlethwaite A.E. A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis. Biochim. Biophys. Acta Aug 2007, 1770(8):1181-1186.
85. Distler J.H., Pisetsky D.S., Huber L.C., et al. Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum. Nov 2005, 52(11):3337-3348.
86. Guiducci S., Distler J.H., Jungel A., et al. The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis Rheum. Sep 2008, 58(9):2845-2853.
87. Kill A., Tabeling C., Undeutsch R., et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res. Ther. 2014, 16(1):R29.
88. Becker M.O., Kill A., Kutsche M., et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am. J. Respir. Crit. Care Med. Oct 1 2014, 190(7):808-817.
89. Eferl R., Hasselblatt P., Rath M., et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc. Natl. Acad. Sci. U. S. A. Jul 29 2008, 105(30):10525-10530.
90. Maurer B., Busch N., Jungel A., et al. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation Dec 8 2009, 120(23):2367-2376.
91. Asano Y., Stawski L., Hant F., et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am. J. Pathol. Apr 2010, 176(4):1983-1998.
92. Asano Y., Bujor A.M., Trojanowska M. The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. J. Dermatol. Sci. Sep 2010, 59(3):153-162.